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The interactions of CD40 and CD40L have been known for some time to critically regulate B-
cell responses with respect to proliferation, isotype switching, antibody production, and memory
formation. More recent findings demonstrated that CD40 can be expressed on several other
antigen-presenting cell (APC) types such as macrophages, dendritic cells, and fibroblasts. This
expression of CD40 regulates T-cell-APC interaction and is centrally involved in a wide array
of inflammatory events. Here, currently available data are reviewed demonstrating that CD40-
CD40L interactions are operational in two chronic inflammatory clinical conditions, namely,
multiple sclerosis and atherosclerosis. The functional correlates of these interactions are
discussed in the light of recent other findings, shedding light on the multiple effects of CD40-
CD40L interactions.
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MULTIPLE ROLES OF CD40-CD40 LIGAND
INTERACTIONS
The past 4 years have seen such a flurry of papers on
the multiple and diverse roles of the CD40-CD40L
receptor pair (reviewed in detail by Laman et al.,
1996; Van Kooten and Banchereau, 1996) that the
interaction of these two molecules has recently been
likened to a "master regulator" of the immune system
(Grewal and Flavell, 1996). Initially, studies focused
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on elucidation of the role of CD40L transiently
expressed on activated T cells in proliferation,
differentiation, and function of CD40-positive B cells.
Signals through CD40 trigger a wide array of B-cell
activities, such as increased expression ofMHC class
II, CD23, CD25, CD69, and CD44, transition ofLFA-
1 to the high-affinity state, proliferation, locomotion,
and homotypic adhesion. In conjunction with appro-
priate cytokines, CD40 ligation leads to antibody
production, isotype switching, and direction ofB cells
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into the memory pathway. The indispensable role of
CD40 ligation and the nonredundancy in CD40L
function is highlighted by the X-linked hyper IgM
syndrome, in which patients lack isotypes other than
IgM and suffer from recurrent infections (see preced-
ing reviews).
More recently, it has become clear that functions of
the CD40-CD40L receptor pair are not just limited to
T cells signaling B cells. CD40 can be expressed on a
wide array of APC, including B cells, follicular
dendritic cells, (interdigitating) dendritic cells, fibro-
blasts, endothelial cells, and macrophages. This
expression on most or all types of APC strongly
suggests that CD40 signals are essential components
of antigen presentation. In this respect, CD40L
ligation has been shown to transduce signals required
for T-cell priming (reviewed by Grewal and Flavell,
1996). However, this notion has been challenged by
findings that some antiviral functions of CD4 T cells
can be primed in a CD40-deficient environment
(Oxenius et al., 1996). Another aspect of T-cell
function is the finding that thymic epithelium
expresses CD40, and that CD40L is involved in
thymic selection of T cells (Foy et al., 1995).
Antibody against CD40L can also inhibit the develop-
ment of murine AIDS (Green et al., 1996), a viral
disease targeting B cells. In addition, CD40L is
required for an effective antiviral memory CD8 T-
cell response (Borrow et al., 1996). With respect to
autoimmune disease, anti-CD40L can interfere with
disease development in mouse models for arthritis
(Durie et al., 1993), systemic lupus erythematosus
(Mohan et al., 1995; Early et al., 1996), and with
disease in a mouse model for multiple sclerosis (MS)
(Gerritse et al., 1996), as discussed in detail in what
follows.
After the landmark paper of Alderson et al. (1993),
which identified functional expression of CD40 on
monocytes, some of the attention has shifted from B
cells to effector functions of macrophages that are
triggered through CD40 ligation, and that contribute
to antigen-specific responses and inflammation. The
different roles of CD40 in inflammation have been
comprehensively reviewed by Stout and Suttles
(1996),b. Some examples are the protective effector
functions of macrophages triggered by CD40 ligation
for immunity against Pneumocystis carinii (Wiley
and Harmsen, 1995) and Leishmania species (Camp-
bell et al., 1996; Kamanaka et al., 1996; Soong et al.,
1996).
In what follows, we review data that we have
obtained recently in two types of clinical chronic
inflammation, namely, multiple sclerosis (MS),
including the animal model for this disease, experi-
mental autoimmune encephalomyelitis (EAE), and
atherosclerosis. We then discuss how these data fit the
currently known functional outcomes of interaction
between CD40 and CD40L for distinct cell types.
CD40 IN MULTIPLE SCLEROSIS AND EAE
CD40 Is Expressed in the Central Nervous
System in MS and EAE
In view of the known roles of CD40-CD40L mediat-
ing interactions between T cells and APC as well as T
cells and B cells, we have previously evaluated this
interaction in EAE in SJL mice. This forms a model
for MS, a chronic inflammatory disease of the central
nervous system (CNS). EAE induced in SJL mice by
immunization with a peptide of the proteolipid protein
(PLP139-15) could be blocked by in vivo treatment
with a monoclonal antibody against CD40L (Gerritse
et al., 1996). Development of disease could be
effectively blocked when antibody was coadminis-
tered with immunization for disease induction, but
also when treatment was started several days after
immunization. However, treatment was not effective
during the later stages of established disease. These
data argued that CD40-CD40L interactions are crucial
for development of EAE, and that they operate at
some point prior to manifestation of clinical signs.
To confirm a role of CD40-CD40L interactions in
MS, we performed immunocytochemistry on frozen
sections from autopsy material. Both abundant
expression of CD40 and limited expression of CD40L
could be demonstrated within perivascular inflamma-
tory infiltrates of mononuclear cells in situ (Gerritse et
al., 1996). Double-staining experiments for mem-
brane expression of CD40 and intracytoplasmicCD40 IN CLINICAL INFLAMMATION 217
activity of acid phosphatase showed that the large
majority of cells expressing CD40 within inflamma-
tory infiltrates belonged to the monocytic lineage.
However, a minor fraction of the cells locally
expressing CD40 could be identified as B cells as they
also contained immunoglobulins (Gerritse et al.,
1996). Currently, we are addressing the mechanisms
by which anti-CD40L antibody treatment prevents
disease in mice. In these experiments, we have found
that CD40 is also expressed in the spinal cord of mice
with EAE (Laman et al., manuscript in preparation).
Using CD40L-deficient mice carrying a transgenic T-
cell receptor for myelin basic protein (MBP), Grewal
et al. (1996) confirmed our previous observations in
anti-CD40L-treated mice, and extended these findings
by showing that adoptive transfer of B7-1 APC could
overcome the defect and supported production of
IFN-y and development of EAE. Collectively, the
data in mice and humans support the view that CD40-
CD40L interactions are essential in these chronic
inflammatory conditions and imply that novel thera-
peutic strategies could be developed with this in
mind.
With the aim to develop animal models applicable
to evaluate therapeutics suitable for use in humans,
we analyzed expression of CD40, CD40L, B7-1, B7-
2, and a panel of pro- and anti-inflammatory cytokines
in the nonhuman primate marmoset species (Calli-
thrix jacchus) (Laman et al., in press, b). Five
marmosets were immunized with myelin purified
from human white matter and suffered from attacks of
acute EAE, corroborating earlier findings (Massacesi
et al., 1995). Similar to the situation in MS, high
levels of expression of CD40 were found within
perivascular and periventricular infiltrates of mono-
nuclear cells in the brain during active disease.
Double staining for CD40 and acid phosphatase as
described before revealed that, as in humans, many
macrophages present within infiltrates express CD40.
However, cells single positive for CD40 were also
present, which probably are B cells or immature
macrophages lacking acid phosphatase activity. In
addition, only a proportion of locally present macro-
phages/activated microglia express CD40. Analysis of
the anatomically restricted expression of CD40 may
provide further clues to the functions of this molecule
in chronic inflammation of the CNS.
Possible Roles of CD40-CD40L Interactions in
MS and EAE
We argue that CD40L expressed on activated T cells
may have functional implications in MS and EAE at
the following levels: transmigration ofT cells through
the (inflamed) endothelium of the blood-brain barrier
and brain parenchyma; T-B-cell interaction leading to
production of specific antibody within the CNS;
priming of T cells and cytokine production; direct
lyric effects of T cells, and finally T-cell macrophage
interaction leading to activation of several different
macrophage effector functions. These issues are
discussed briefly in what follows.
CD40 is expressed by inflamed endothelium (e.g.,
Hollenbaugh et al., 1995; Karmann et al., 1995), and
ligation leads to increased expression of several
adhesion molecules (see Table I), thereby improving
extravasation of mononuclear cells. CD40-CD40L
interaction can mediate production of metalloprotei-
nase (MMP-I: collagenase) by T cells, which may
improve transmigration of T cells (Dollery et al.,
1995; Miltenburg et al., 1995).
Signals through CD40L are required for T-cell
priming in several experimental settings (Grewal et
al., 1995; Van Essen et al., 1995; reviewed by Grewal
and Flavell, 1996), but not others (Oxenius et al.,
1996). Expression of CD40 on APC either in the
periphery or within mononuclear cell infiltrates (on
macrophages) of the CNS in MS and EAE may serve
this purpose. Peng et al. (1996) have shown that
triggering T cells through CD40L leads to production
of both Thl and Th2 cytokines in vitro (see Table 1).
A study by Vergelli et al. (1996) demonstrated that a
novel population of CD4+CD56 myelin-reactive T
cells lyses target cells expressing CD56/neural cell
adhesion molecule. It will be of interest to determine
whether these cells express CD40L and whether
ligation influences lytic activity.
Autoantibodies contribute to development of MS
and EAE. T-B-cell interaction guided by CD40-218 JON D. LAMAN et al.
TABLE Functions of CD40-CD40L Interactions in Relation to Multiple Sclerosis and Atherosclerosis
Antigen presentation:




Increased expression of CD23, CD25, CD69, and CD44
Isotype switching
Antibody production
Production of cytokines and other soluble factors:
Macrophages: IL-1, IL-6, IL-8, IL-12, TNF-a, and NO by macrophages
T cells: IL-2, IL-4, IL-5, and IL-10 by T cells
Metalloproteinases: MMP-1/collagenase by T cells and MMP-9/gelatinase B by macrophages
Fibroblasts: IL-6
Transmigration of mononuclear cells:
Expression of CD40 on inflamed endothelium
Increased expression of E-selectin, VCAM-1, and ICAM-1 after CD40 ligation
Tissue restructuring:
Proliferation of fibroblasts
Increased expression of ICAM-1 and VCAM-1 by fibroblasts
CD40L is required for the thymus-dependent anti-
body response against protein components of the
myelin sheath such as MBP and PLP. It was shown
previously that antibody forming cells against MBP
are present within mononuclear cell infiltrates in MS
tissue (Gerritse et al., 1993, 1994).
Macrophages can potentially contribute to myelin
loss and local inflammation in many ways, including
(auto)-antigen presentation, production of cytokines
and chemokines, proteolytic enzymes, nitric oxide,
reactive oxygen species, and lipid peroxidation. In
vivo depletion studies of macrophages have confirmed
the requirement for this cell type in development of
EAE (Huitinga et al., 1995). In addition, transgenic
mice expressing the macrophage/microglia cytokine
gene IL-3 in astrocytes show infiltration of macro-
phages but not lymphocytes, in conjunction with
primary demyelination and motor deficits (Chiang et
al., 1996). The role of macrophages is further
supported by the finding that neutralization of the
macrophage inflammatory protein-a (MIP-1 c) inhib-
its disease (Karpus et al., 1995).
Macrophage functions relevant to MS and EAE
that can be triggered through CD40 include improved
APC function through upregulation of ICAM-1, MHC
class II, CD86, and CD40 itself (Kiener et al., 1995);
production of proinflammatory cytokines (TNF-a, IL-
l/3, IL-6, IL-8, and IL-12p40) (Alderson et al., 1993;
Wagner et al., 1994; Kiener et al., 1995; Shu et al.,
1995; Kato et al., 1996) (see also Table I). Probert et
al. (1995) have shown that a transgenic mouse strain
expressing TNF-c in the CNS has macrophage
infiltration, demyelination, and severe neurological
disease. The role of IL-12, a typical Thl proin-
flammator cytokine (reviewed by Seder et al., 1996),
deserves special attention in the light of CD40-
CD40L interactions. IL-12 promotes the development
of EAE (Leonard et al., 1995), probably by stimulat-
ing the development of naive CD4 T cells into Thl
cells producing IFN-y, but not IL-4. Shu et al. (1995)
have argued that antigen presentation by monocytes
may favor persistence of Thl responses as production
of IL-12 by monocytes can in turn provoke INF-y
production by Thl and Th0 cells. In support of this,
Stuber et al. (1996) have shown that the same
antibody we used to prevent EAE in mice (Gerritse et
al., 1996) inhibits IL-12 production and thereby may
prevent priming of T cells. Interestingly, two recent
papers have shown that mouse dendritic cells pro-
duced high levels of IL-12 in response to CD40L,
even in the absence of cognate antigen recognition
(Cella et al., 1996; Koch et al., 1996). In addition,
links exist between CD40L expression and production
of IL-12 and NO, both in EAE (Waldburger et al.,
1995) and in cell-mediated immunity against Pneu-
mocystis carinii (Wiley and Harmsen, 1995) andCD40 IN CLINICAL INFLAMMATION 219
Leishmania species (Campbell et al., 1996; Kama-
naka et al., 1996; Soong et al., 1996).
Possible Roles of CD40-CD40L Interactions in
Atherosclerosis
CD40 IN ATHEROSCLEROSIS
CD40 Is Expressed in Atherosclerotic Lesions
In view of our previous findings in MS and EAE, we
considered the possibility that CD40-CD40L inter-
actions are involved in aspects of atherosclerosis as
well (Laman et al., 1997). This disease results from an
extremely complex and only partly understood inter-
play among diverse components such as cholesterol
metabolism, hemodynamic stress, the blood coagula-
tion system, and risk factors such as obesity and
smoking. The immune system is critically involved in
atherosclerosis, as evidenced by high numbers of
activated T cells and macrophages within athero-
sclerotic plaques (Hansson and Libby, 1996; Raines et
al., 1996), and the involvement of mononuclear cells
in production of cytokines and growth factors (Libby
and Ross, 1996).
To assess the hypothesis that CD40-CD40L inter-
actions play a role in atherosclerosis, we analyzed the
expression of CD40 by means of immunohistochem-
istry on frozen sections from human plaque material.
Atherosclerosis patients were surgically treated to
remove plaques from the carotid artery (endarter-
ectomy). CD40 was expressed in different regions of
the plaque, and by cell types with distinct morpho-
logies (Fig. lc and ld). To assess whether CD40 was
expressed by macrophages within the plaque, double
staining was performed for CD40 (blue in Figure d)
and acid phosphatase, a lysosomal enzyme character-
istic for macrophages (red in Fig. d). As double-
staining cells were clearly present, we concluded that
at least part of the CD40-expressing cells within
plaques are macrophages.
A much wider analysis of the extent of CD40 (and
CD40L) expression during atherosclerosis taking into
account different clinical conditions, different loca-
tions and age of plaques, and anatomic sites within
plaques now seems warranted as a basis to elucidate
roles of CD40-CD40L interactions in this disease.
We argue that CD40-CD40L interactions could affect
the atherosclerotic process at different levels, includ-
ing transmigration of mononuclear cells into plaque
areas; activation of T cells and cytokine production;
activation of several macrophage effector functions;
local antigen presentation; tissue restructuring
through combined activities of T cells, macrophages,
and fibroblasts.
The role of CD40 on endothelium, transmigration
of cells, and production of cytokines by T cells has
been addressed in the preceding section on EAE. The
macrophage effector functions activated by CD40
ligation that may be operational in atherosclerotic
plaques include adherence to CD40L-expressing
cells, homotypic aggregation, and increased survival
of cells, probably through protection from apoptosis
Alderson et al., 1993). Furthermore, the antigen-
presenting function can be improved through upregu-
lation of accessory molecules (ICAM-1, MHC class
II, B7-2, and CD40). With regard to bioactive
compounds, CD40 ligation can costimulate NO
production and secretion of the proinflammatory
cytokines TNF-c, IL-1/3, IL-6, IL-8, and IL-12 (see
Table and references cited before). CD40L can also
induce production of gelatinase B by monocytes and
fibroblasts (Malik et al., 1996). Interestingly, by this
mechanism, macrophages can digest collagen present
in the fibrous cap of atherosclerotic plaques, and as
such may contribute to fissure and release of the cap,
leading to life-threatening occlusions of arteries
(Galis et al., 1994). Fibroblasts express CD40 (Fries
et al., 1995) and proliferate in response to CD40L
signals (Yellin et al., 1995), suggesting that CD40-
CD40L may act as a regulator of fibroblast expan-
sion.
CONCLUDING REMARKS
In this review, we have attempted to highlight the
important similarities between expression and
possibly function of CD40-CD40L in multiple sclero-
sis and EAE on the one hand, and atherosclerosis onCD40 IN CLINICAL INFLAMMATION 221
data discussed here are derived from ongoing collab-
orations with Randy Noelle (Dartmouth Medical
School, Lebanon, NH) and Bart de Smet (ICIN,
Utrecht, the Netherlands). Marjan van Meurs and
Arjan Schoneveld are gratefully acknowledged for
expert immunocytochemistry.
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